Clinical trials
Juvenile Idiopathic Arthritis clinical trials
Below are recruiting juvenile idiopathic arthritis clinical trials, each written for real people, not researchers. We’re tracking 48 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07517575RecruitingPhase 2
Olokizumab for Children with Juvenile Idiopathic Arthritis
This trial tests a new medicine called olokizumab in children and teenagers with juvenile idiopathic arthritis (JIA)—a condition where the immune system causes joint inflammation and pain. The study checks if this drug is safe and effective for children whose arthritis hasn't improved enough with standard treatments.
Kazan'Ages 2–17 - NCT07554495RecruitingPhase 3
Filgotinib for moderate to severe polyarticular juvenile arthritis
This trial tests filgotinib, a new medication that may help reduce joint swelling and pain in children and teens (ages 8–17) with polyarticular juvenile idiopathic arthritis—a type of childhood arthritis affecting multiple joints. You're eligible if your current arthritis medicines haven't worked well enough.
LeuvenAges 8–18 - NCT07386587Enrolling by invitationPhase 3
Methotrexate plus etanercept for juvenile arthritis
This study compares methotrexate alone versus methotrexate combined with etanercept to see which works better for children with polyarticular juvenile idiopathic arthritis. The goal is to help children achieve low disease activity quickly.
Lahore, Punjab ProvinceAges 2–16 - NCT06869551RecruitingPhase 3
Testing a New Drug for Juvenile Psoriatic Arthritis
This study tests an investigational drug called Deucravacitinib to see if it can safely and effectively treat Juvenile Psoriatic Arthritis in children. You may be able to join if standard treatments haven't helped enough.
Lancaster, CaliforniaAges 5–17 - NCT04804553RecruitingPhase 3
Apremilast for children with active juvenile psoriatic arthritis
This Phase 3 trial tests apremilast to treat active juvenile psoriatic arthritis (joint inflammation) in children and teens. You may be able to join if your child’s condition is active despite prior treatments or if they couldn’t tolerate them.
BregenzAges 5–17 - NCT06751238RecruitingPhase 1
Secukinumab for children with psoriatic arthritis
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
Gainesville, FloridaAges 2–17 - NCT06888973Enrolling by invitationPhase 1/Phase 2
Stem cell infusion for autoimmune diseases
This clinical trial is testing if infusions of special stem cells (called mesenchymal stem cells) can help people with certain autoimmune diseases where standard treatments have not worked well enough. It is an early-phase study in Pakistan for adults (and some children for one condition) with rheumatoid arthritis, lupus, systemic sclerosis, ankylosing spondylitis, or dermatomyositis/polymyositis.
RawalpindiAges 18–50 - NCT03510442Recruiting
Study of joint illness patterns and genes in juvenile and adult diseases
This study follows people with systemic juvenile idiopathic arthritis (sJIA), adult-onset Still’s disease (AOSD), and similar conditions to learn how the illness works over time. It also collects blood and family information to study genetics and explain what causes flare-ups, which may help future care.
Bethesda, MarylandAges 1 day–100 years - NCT04833465Recruiting
Testing a new outcome measure in kids with rheumatology diseases
This study looks at how to measure treatment success in children with juvenile idiopathic arthritis (JIA), lupus (SLE), or fibromyalgia (FM). It may help doctors track symptoms more reliably over time.
Washington D.C., District of ColumbiaAges 5–21 - NCT03913962Recruiting
Exercise study for children with chronic or autoimmune conditions
This study looks at how physical activity affects muscle, metabolism (how your body uses energy), and body composition in children with certain chronic or autoimmune conditions. It may help doctors understand what types of exercise and monitoring are most beneficial and safe.
Clermont-FerrandAges 6–18 - NCT04902807Recruiting
Tool to help decide diagnosis and treatment in immune disorders
This trial tests a tool (a way of collecting health information) to help doctors make better diagnosis, prognosis, and treatment decisions for children with certain immune problems. It also includes healthy children (like relatives) as comparison groups, to see how well the tool works.
ParisAges 1–18 - NCT05310799Recruiting
Personalized risk estimates for children with newly diagnosed JIA
This study looks at how best to estimate a child’s likely symptoms and treatment response in the first phase after a new JIA diagnosis. It may help families and clinicians make clearer, more personalized decisions about care.
Vancouver, British ColumbiaAges 1–18 - NCT06184100Recruiting
Online Self-Management Program for Teens with JIA
This study tests an online self-management program for teens with newly diagnosed JIA. It helps you learn skills to manage your condition, connect with others, and feel more in control.
Calgary, AlbertaAges 12–17 - NCT06376149Recruiting
Making Mindfulness Matter for Kids with JIA
This study tests a program called Making Mindfulness Matter (M3) for children with JIA. It is an online program that helps children and their caregivers learn mindfulness skills to manage pain and stress from arthritis.
Hamilton, OntarioAges 4–12 - NCT06838143Recruiting
Ilaris real-world study for periodic fevers and sJIA
This study watches how people with certain periodic fever syndromes or a severe type of childhood arthritis (sJIA) do on the medicine Ilaris during their regular doctor visits. It collects information to see how well the medicine works in everyday care.
SeoulAges 2–100 - NCT06862843Recruiting
Family eating habits and chronic inflammation study
This study looks at how eating habits and family health history relate to chronic inflammatory conditions like Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It aims to understand these links by studying families with a child or adult affected by these conditions, as well as healthy families.
Florence, ItalyAges Any age - NCT06870045Recruiting
Walking ability test in children with JIA
This study looks at how well children with JIA (arthritis in one knee) can walk and balance, using a simple test called the Dynamic Gait Index. It aims to find a better way to measure walking problems in kids with JIA.
Istanbul, TurkeyAges 8–16 - NCT07065747Recruiting
Understanding inflammation in uveitis using advanced eye imaging
This study uses a special eye scan (OCT) to measure and classify inflammatory cells inside the eye. It aims to better understand different types of uveitis and improve diagnosis and treatment.
Portland, OregonAges 5–85 - NCT07185750Recruiting
Pain Catastrophizing in Parents of Children with JIA
This study looks at how parents of children with juvenile idiopathic arthritis (JIA) think about and react to pain. It aims to understand how parents' worry about pain might affect their child's experience.
Çankaya, AnkaraAges 7–18 - NCT07243782Recruiting
Study of Cosentyx for skin and joint conditions in Korea
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
Seoul, SeoulAges 6–100 - NCT07517250Recruiting
Study of Canakinumab for Fever and Joint Disease
This is a study looking back at patients who were already treated with a medicine called canakinumab for familial Mediterranean fever or Still's disease (rare conditions that cause fevers and joint pain). Researchers want to understand how well this medicine worked over time and what happened to patients who took it.
BaselAges 1 year+ - NCT07553182RecruitingPhase 3
Continuing filgotinib treatment for juvenile arthritis
This study lets young people who benefited from filgotinib (a medication that reduces inflammation) in a previous trial continue taking it to see if it stays safe and effective over a longer period. It's designed for patients ages 8–17 who did well on this medicine before.
Le Kremlin-BicêtreAges 8–18 - NCT07602595Recruiting
Understanding pain after childhood rheumatic disease or surgery
This study helps researchers learn how young adults (ages 14–26) who had rheumatic disease or orthopedic surgery as children experience pain over time. By understanding your story, the study may help doctors better support others facing similar challenges.
Cincinnati, OhioAges 14–26 - NCT06100744RecruitingPhase 3
Comparing two drugs for children with psoriatic arthritis
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Little Rock, ArkansasAges 5–17
Hear when a new Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for juvenile idiopathic arthritis?
- Yes. Clin2 currently lists 48 recruiting juvenile idiopathic arthritis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a juvenile idiopathic arthritis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a juvenile idiopathic arthritis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.